When the little fish tries to eat the big fish… in hopes of becoming the biggest fish!

I think the Australian Clinical Labs (ASX: ACL) is likely to fall in the short term as the Morrison government moves to restrict PCR testing.

It’s always sad when the thesis breaks but it is best to acknowledge it.

Austalian Clinical Labs shares are expected to rise as the company has announced yet another earnings upgrade due to high covid testing.

The covid situation is always changing so it’s time to check in on this trade thesis.

The ASX:ACL share price hit all time highs after its upgraded 1H FY2022 guidance, so high covid testing volumes are making ACL stock go up.

Australian Clinical Labs (ASX:ACL) will benefit from high levels of covid testing in Australia.